0001209191-20-012479.txt : 20200225
0001209191-20-012479.hdr.sgml : 20200225
20200225163359
ACCESSION NUMBER: 0001209191-20-012479
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200221
FILED AS OF DATE: 20200225
DATE AS OF CHANGE: 20200225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gilbert Halley E
CENTRAL INDEX KEY: 0001601360
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 20651194
MAIL ADDRESS:
STREET 1: C/O IRONWOOD PHARMACEUTICALS, INC.
STREET 2: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-21
0
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001601360
Gilbert Halley E
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
0
1
0
0
Chief Admin Officer & SVP
Class A Common Stock
2020-02-21
4
S
0
2753
11.63
D
278566
D
Class A Common Stock
2020-02-21
4
S
0
3410
11.63
D
275156
D
Class A Common Stock
2020-02-21
4
S
0
2984
11.63
D
272172
D
Class A Common Stock
2020-02-21
4
S
0
6181
11.63
D
265991
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
/s/ Conor Kilroy, Attorney-in-Fact
2020-02-25